What is Interferon beta-1b SubQ Injection?
Category: Prescription Drugs
Most popular types: Betaseron Betaferon Extavia Show all
Interferon beta-1b is a drug in the interferon family used to treat multiple sclerosis. It is administered by subcutaneous injection and has been demonstrated to slow the advance of the condition as well as reduce the frequency of attacks.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 7509 | 776 | |
| General health | 19 | 13 | |
| Fatigue | 14 | 12 | |
| Stiffness/spasticity | 9 | 2 | |
| Improve mobility | 8 | 4 | |
| Walking problems | 8 | 3 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 128 | |
| Moderate | 205 | |
| Mild | 284 | |
| None | 178 |
Commonly reported side effects and conditions associated with Interferon beta-1b SubQ Injection
| Side effect | Patients | Percentage |
|---|---|---|
| Injection site pain | 103 | |
| Bruising | 73 | |
| Headaches | 65 | |
| Depressed mood | 47 | |
| Fever | 41 | |
| Elevated liver enzymes | 20 |
Why patients stopped taking Interferon beta-1b SubQ Injection
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Side effects too severe | 418 | |
| Doctor's advice | 368 | |
| Did not seem to work | 364 | |
| Other | 202 | |
| Expense | 39 | |
| Change in health plan coverage | 37 | |
| Personal research | 31 | |
| Course of treatment ended | 23 |
Duration
Stopped taking Interferon beta-1b SubQ Injection
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 61 | |
| 1 - 6 months | 175 | |
| 6 months - 1 year | 149 | |
| 1 - 2 years | 181 | |
| 2 - 5 years | 227 | |
| 5 - 10 years | 122 | |
| 10 years or more | 81 |
What people switch to and from
Patients started taking Interferon beta-1b SubQ Injection after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Glatiramer acetate (Copaxone) | 19 | |
| Interferon beta-1a IM Injection (Avonex) | 11 | |
| Natalizumab (Tysabri) | 5 | |
| Dimethyl fumarate (Tecfidera) | 4 | |
| Interferon beta-1a SubQ injection (Rebif) | 3 |
Patients stopped taking Interferon beta-1b SubQ Injection and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Glatiramer acetate (Copaxone) | 34 | |
| Dimethyl fumarate (Tecfidera) | 33 | |
| Natalizumab (Tysabri) | 33 | |
| Fingolimod (Gilenya) | 23 | |
| Teriflunomide (Aubagio) | 16 |
Last updated: